<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379990</url>
  </required_header>
  <id_info>
    <org_study_id>RA4104917</org_study_id>
    <nct_id>NCT00379990</nct_id>
  </id_info>
  <brief_title>A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Synovial Thickness and Vascularity of 28 Days Repeat Dosing of GW274150 or 7.5mg Prednisolone in RA Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory study to examine the effect of iNOS inhibition in rheumatoid arthritis
      patients. The study involves 28 days repeat dosing with GW274150 (dose determined by the
      results from a previous study), prednisolone (7.5mg) or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurment of synovial vascularity</measure>
    <time_frame>Day 1, Day 15 and Day 28</time_frame>
    <description>Power Doppler ultrasonographic measurement of synovial vascularity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Synovial thickness</measure>
    <time_frame>Day 1, 15 and 28</time_frame>
    <description>High frequency ultrasound measurement of synovial thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: ECG</measure>
    <time_frame>Day 1, 15 and 28</time_frame>
    <description>12-lead ECG meaurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Vital Signs</measure>
    <time_frame>Day 1, 15 and 28</time_frame>
    <description>Blood pressure and heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Laboratory</measure>
    <time_frame>Day 1, 8, 15, 22, 28 and Follow Up</time_frame>
    <description>Laboratory assessments including liver function tests, amylase and lipase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>Day 15 and Day 28</time_frame>
    <description>Maximum plasma concentration of GW274150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Trough</measure>
    <time_frame>Days 8,15 and Day 28</time_frame>
    <description>Trough plasma concentration of GW274150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Day 1 to Day 28 and Follow Up</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>GW274150 60 mg once daily for 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg GW274150 taken once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone 7.5 mg once daily for 28 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7.5 mg prednisolone taken once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily for 28 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW274150</intervention_name>
    <description>60 mg /day</description>
    <arm_group_label>GW274150 60 mg once daily for 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>7.5 mg/day</description>
    <arm_group_label>Prednisolone 7.5 mg once daily for 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo once daily for 28 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of rheumatoid arthritis according to the revised 1987 criteria of the
             American College of Rheumatology

          -  Female subjects who are not capable of becoming pregnant

          -  Active disease defined as Disease Activity Score (DAS) 28 = 4.0 and at least one
             metacarpal-phalangeal finger (MCP) joint with either detectable vascularity or
             thickness

          -  Stable doses of disease modifying anti-rheumatic drugs (DMARDs), (which can include
             but is not restricted to methotrexate, sulphasalazine and hydroxychloroquine in any
             combination) for 8 weeks prior to enrollment

          -  Patients receiving methotrexate must be on stable folate supplements

          -  Must have been on stable doses for 2 weeks prior to screening if using COX inhibitors

          -  Signed consent form

          -  The patient is able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions

        Exclusion criteria:

          -  The subject is using, or has used, oral glucocorticoids within 8 weeks of enrollment

          -  The subject is currently receiving anti-rheumatic biological therapy (e.g. infliximab,
             adalimumab, etanercept or anakinra)

          -  The subject received their final dose of infliximab or adalimumab within 3 months of
             enrollment

          -  The subject received their final dose of etanercept or anakinra within 1 month of
             enrollment

          -  The subject has received another investigational drug within 30 days

          -  The subject drinks more than 28 units (male) or 21 units (female) of alcohol in a week

          -  History of liver or renal disease in the 6 months prior to screening

          -  The subject has a history of drug or other allergy

          -  Subject is positive for Hepatitis B and C or HIV virus

          -  The subject has positive pregnancy test

          -  The subject has positive test for drugs of abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W6 8LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Serbia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2006</study_first_posted>
  <disposition_first_submitted>July 22, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>July 22, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iNOS</keyword>
  <keyword>Exhaled NO</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 24, 2017</submitted>
    <returned>February 9, 2018</returned>
    <submitted>March 6, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

